INSTITUTE BIOSAFETY COMMITTEE
Chairperson: Chunling Dai

Minutes

Institution: New York State Institute for Basic Research in Developmental Disabilities (IBR)

Meeting Date: 07.15.26

Meeting Time: 1:00 PM

Meeting Type: Virtual

IBC Members Present:

1. Chunling Dai (*IBC Chair*)
2. Karen Amble (*IBC Member/IBR Deputy Director*)
3. Augusta D'Amico (*IBC Member/Director of Clinical Services*)
4. Lorena Legisi-Sejdaras (*Biological Safety Officer/Director, Office of Laboratory Safety and Training*)
5. Ashfaq Sheikh (Lab Rep.)
6. Wen Hu (Lab Rep./Animal Expert)
7. Xue-Ying He (Lab Rep.)
8. Dorota Ziemnicka (Lab Rep.)
9. Christopher Corbo (Local Non-affiliated Member)
10. Sonal Goswami (Lab Rep.)

IBC Members Absent:

1. Fang Du (Lab Rep./Animal Expert)

Quorum: Present

Other Individuals in Attendance: None

Call to Order: 1:05PM

Conflicts of Interest:

The Chair reminded all members present to identify any conflicts of interest as each registration is reviewed.

Review and Approval of Previous Meeting Minutes:

A member moved to approve June 17, 2026 minutes, as written. Another member seconded the motion.
The Committee voted unanimously to approve the minutes.

Review of Prior Business:

- Laboratory Safety Showers

INSTITUTE BIOSAFETY COMMITTEE
Chairperson: Chunling Dai

2026 Annual Review:
A member moved to approve the annual updates. Another member seconded the motion.
The Committee voted unanimously to approve the annual updates as per the following statuses.

IBC-2012-002 a	Elizabeth Lennon	Developmental Follow-Up Program: Arousal and Attention in High-Risk Children: A Prospective Study	**No Change**
IBC-2025-004	Felicia Balsamo	Characterizing the Natural History of Fragile X Syndrome to Inform the Development of Intervention Outcome Measures (FORWARD MARCH)	**No Change**

Amended Applications:

A) **IBC-2011-005-** Effect of Diet with Walnuts on the Levels of Amyloid-Beta Protein, and Markers of Oxidative Stress and Inflammation in the Tissues of Animal Model of Alzheimer's Disease by Abha Chauhan.

- Pending. PI needs to address questions regarding the project.

B) **IBC-2024-001-** Mechanisms of early intervention after traumatic brain injury in rodent models of posttraumatic epilepsy by Sonal Goswami.

1. Reviewer 1 recommends approval of this protocol. The amendment does not have significant changes, only the personnel change.

2. Reviewer 2 recommends approval of this amendment because the proposed change is limited to the addition of Dr. Aditi Naik.

3. Biological Safety Officer recommends approval. There are no changes to the approved recombinant material, procedures, or biosafety practices.

C) **IBC- IBC-2024-003-** Developing a novel Spontaneous Nanoliposome Antigen Particle (SNAP) vaccine targeting a-synuclein by Chunling Dai.

1. Reviewer 1 recommends approval of the minor changes to the general information. No additional biosafety concerns were identified based on the proposed modifications.

2. Reviewer 2 recommends approval of the amended protocol.

3. Biological Safety Officer
   a) NIH Guidelines Section- None. No recombinant DNA used.

   b) Risk Assessment and Discussion-The PI submitted the Chemical Hazard Risk Assessment for the use of Sodium Azide.

   c)Training
   - The PI and the collaborator meet all the training requirements.

d) Biosafety Level Assignment
- The biosafety containment levels at which each of the project's operations will occur is BSL-2.

D) **IBC-2024-004-** Testing the effects of roburic acid on Alzheimer's disease (AD)-like pathologies in AD mouse model by Chunling Dai.

- PI closed the protocol.

E) **IBC-2019-005-** Extracellular tau, a promising target for Alzheimer's disease, cognitive aging and brain injury by Chunling Dai.

- PI closed the protocol.

New Applications:

A) IBC Protocol **IBC-26-03** – Cell biology of TPP1/CLN2 protein by Adam Golabek.

- Pending subcommittee review.

B) **IBC 26-01**- Developing 3D Human iPSC-Derived Neuronal Platforms for Epilepsy Modeling and Drug Discovery by Sonal Goswami.

1.Reviewer 1 recommends approval. In this project, the Principal Investigator (PI) will be using commercially available viruses that fall under Risk Group 1. These viruses are not known to cause disease in healthy adults.

2. Reviewer 2 recommends approval, and no additional biosafety concerns were identified based on the proposed protocol.

.

3. Biological Safety Officer:

a) NIH Guidelines Section
- Section II and Appendix B, and Section III-D
  AAV1-tdTomato (pENN.AAV.CAG.tdTomato.WPRE.SV40) expressed tdTomato in organoid cells using the robust CAG promoter.
  AAV1-Syn.GCamp6f.WPRE.SV40 expresses a genetically encoded calcium indicator under the pan-neuronal synapsin promoter.
  (Samarasinghe et al. 2021, Nat Neurosci.)

b) Risk Assessment and Discussion
- This project involves agents with recombinant and synthetic AAV constructs, which are Risk Group I agents that are not associated with diseases in healthy adults. There are chemicals of interest; the PI did submit the Chemical Hazard Assessment form.

c) Training
- The PI and the collaborator meet all the training requirements.

d) Biosafety Level Assignment
- The biosafety containment levels at which each of the project's operations will occur is BSL-2.

New Business:
- None

Review of Incidents:

(The NIH Guidelines require that significant incidents, violations, and research-related accidents and illnesses be reported to NIH OSP.)

- Nothing to report at this time.

Inspections/ Ongoing:

(Section IV-B-2-b-(5) of the NIH Guidelines requires IBCs to periodically review to ensure compliance with the NIH)
- None

Public Comments:

- There were no public comments.

Adjournment:

A member moved to adjourn the meeting at 1:15 PM. Another member seconded the motion.